Vasomedical, Inc. is a global leader in non-invasive healthcare solutions and products with corporate offices and manufacturing in Plainview, New York. We also have manufacturing facilities in China. Our proprietary core product line of Enhanced External Counterpulsation (EECP®) Therapy systems is the leading product in the non-invasive treatment of cardiovascular disease. Vasomedical is the parent company of our operating subsidiaries - Vasomedical Solutions, Vasomedical Global and VasoHealthcare. The Company is listed on the OTCBB under the symbol VASO. The Company is pursuing a strategy of accretive acquisitions in the medical device and health care markets and promoting growth in our core businesses.
Vasomedical Solutions (VasoSolutions), is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) Therapy systems, BIOX™ ECG Holter and Ambulatory Blood Pressure Monitoring products and EZ™ O2 Oximeters and ECG monitors. VasoSolutions, located in Westbury NY, is a cGMP and ISO13485 Annex II quality process certified medical manufacturer.
The Company’s proprietary EECP® is an FDA cleared, non-invasive medical therapy for the treatment of chronic stable angina that is refractory to optimal anti-anginal medical therapy without options for revascularization. The Company provides hospitals, clinics and private practices with EECP® systems and customer support services that include clinical, marketing and technical support programs. Clinical training and other support programs are designed to provide optimal clinical and financial outcomes in the private practice, clinic or hospital setting.
Click here to visit the VasoSolutions website >
VasoHealthcare signed a sales representative agreement in May 2010 with GE Healthcare, the healthcare business unit of GE, for the sale of select GE Healthcare Diagnostic Imaging products. VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and District of Columbia.
The VasoHealthcare team of highly qualified sales professionals and management match GE Healthcare’s exceptionally high requirements and meet the challenges of today’s highly technical and rapidly changing market. VasoHealthcare is a sales organization of over 70 highly qualified and experienced sales professionals, seasoned sales managers and support personnel specializing in high-tech medical equipment sales, led by an experienced executive management team.
Our representation agreement with GE Healthcare is an example of Vasomedical’s strategy to expand its operations into new areas of potential growth in healthcare. Based upon the future needs of the worldwide medical marketplace and the potential for growth in revenue and shareholder value, Vasomedical will continue to explore new and exciting opportunities designed to improve the delivery of healthcare and significantly contribute to the quality of life.
Click here to visit the VasoHealthcare website >
Vasomedical Global Corp. (VasoGlobal), has been established to manage the operations of the Company’s recently acquired Chinese companies; as well as identify and manage potential accretive acquisitions the Company may consider.
“The completion of our accretive acquisitions is an important step of our global strategy. The consolidation of resources and vertical integration of our businesses situates Vasomedical well in the rapidly changing and challenging medical marketplace to realize its vision to be a global leader.” -Dr. Jun Ma, President & CEO
Biox Instruments Co., Ltd., is a leading developer and manufacturer of ambulatory monitoring devices. Located in Wuxi, Jiangsu, China, Biox has been Vasomedical’s partner on the BIOX™ series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems.
Click here to visit the BIOX website >
Life Enhancement Technologies (LET), based in Foshan, Guangdong, China, has been a technology and alternate manufacturing source for Vasomedical’s proprietary Enhanced External Counterpulsation (EECP®) Therapy systems, including certain Lumenair™ systems and all AngioNew® systems for over 15 years.